S-1/A: First Choice Healthcare Pivots to Primary Care, Seeks $12M IPO

First Choice Healthcare Solutions is undergoing a strategic transformation, shifting from orthopedic services to a national network of primary care and wellness clinics, supported by a $12 million public offering.

Summary

• First Choice Healthcare Solutions (FCHS) is pivoting its business strategy from historical orthopedic services to developing a national chain of innovative primary care and wellness clinics, focusing on life improvement services (anti-aging, weight management, hormone replacement) and pharmacy services.
• The company plans to terminate all remaining legacy orthopedic and physical therapy services concurrently with the completion of the public offering.
• FCHS has entered into a definitive agreement to acquire Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC (collectively 'Pointe Med Pharmacy') for $15.8 million, payable in cash, debt assumption/payoff, stock issuance, earn-out, and performance bonus.
• An asset purchase agreement was also signed to acquire physical and intangible assets, including 'The Good Clinic' trademark, from The Good Clinic, Inc. for $3.5 million in an all-stock deal.
• Operations for the new primary care and wellness clinics are expected to commence starting October 1, 2025.
• The company is offering up to 2,400,000 shares of Series D Convertible Preferred Stock and warrants to purchase an equal number of Series D Convertible Preferred Stock, with a combined public offering price of $5.00 per share/warrant.
• Net proceeds from the offering are expected to be approximately $10,640,000, or $12,296,000 if the over-allotment option is fully exercised.
• Proceeds will be used primarily for acquisitions ($9,000,000), hiring key personnel ($400,000), working capital ($740,000 $2,396,000), and marketing expenses ($500,000).
• A 1-for-2,000 reverse stock split, approved on September 15, 2024, will be effected immediately after the registration statement's effectiveness but prior to NYSE listing, applicable to existing common shares but not to shares issued in the IPO, resale shares, or acquisition-related shares.
• Lance Friedman, the current CEO, holds all 4 outstanding shares of Series A Super Voting Preferred Stock, which will be cancelled upon completion of the offering.
• The company aims to list its common stock on the NYSE under the symbol FCHS, contingent on raising at least $10.0 million in the offering.
• FCHS reported net losses of $3.5 million for the nine months ended September 30, 2025, and $3.8 million for the year ended December 31, 2024.
• The accumulated deficit for FCHS was approximately $71.3 million as of September 30, 2025.
• Pointe Med/LiveWell, the acquired entity, reported net income attributable to shareholders of $1.44 million for the nine months ended September 30, 2025, and $1.41 million for the year ended December 31, 2024.
• Pointe Med/LiveWell's gross profit margin was 85% for the nine months ended September 30, 2025, and 85% for the year ended December 31, 2024.

Sentiment

Score: 3

Explanation: The company is undergoing a significant strategic pivot into a high-growth market, which is a positive. However, it carries substantial financial risks, including a history of significant losses, a large accumulated deficit, and a going concern warning. The success of the capital raise and integration of acquisitions is critical and uncertain, leading to a cautious outlook.

Positives

• The strategic pivot to primary care and wellness clinics, including anti-aging, weight management, and hormone replacement, targets high-growth healthcare market segments.
• Acquisitions of Pointe Med Pharmacy ($15.8 million) and The Good Clinic ($3.5 million) provide established operations and intellectual property for the new strategy.
• The business model leverages Nurse Practitioners, offering an approximate 25% margin improvement over traditional primary care offices staffed with medical doctors.
• The company plans to utilize a centralized administrative infrastructure to achieve economies of scale in billing, collections, purchasing, advertising, and compliance, aiming to sustain profit margins.
• Pointe Med/LiveWell, the acquired entity, has demonstrated profitability with net income of $1.44 million for the nine months ended September 30, 2025, and a strong gross profit margin of 85%.
• The internal compounding pharmacy (LiveWell Drugstore) is expected to provide personalized prescription medications at lower costs and attractive margins, enhancing the patient experience and revenue opportunities.
• The EMR system is Meaningful Use compliant, enabling incentive payments from the U.S. government and reducing hazards associated with disparate healthcare information systems.
• The cancellation of Series A Super Voting Preferred Stock held by the CEO will eliminate concentrated voting power, aligning with corporate governance standards for NYSE listing.

Negatives

• FCHS has a history of significant net losses, including $3.5 million for the nine months ended September 30, 2025, and $3.8 million for the year ended December 31, 2024.
• The company has a substantial accumulated deficit of approximately $71.3 million as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• FCHS has experienced recurring cash outflows from operations, totaling $0.55 million for the nine months ended September 30, 2025, and $1.7 million for the year ended December 31, 2024.
• The company's ability to continue as a going concern is dependent on successfully acquiring profitable companies, growing revenue, reducing costs, and accessing additional capital, which is not assured.
• The former CEO pled guilty to securities fraud, which tarnished the company's reputation and led to litigation and bankruptcy.
• Existing stockholders will experience immediate and substantial dilution from the public offering, as the offering price exceeds the pro forma as adjusted net tangible book value per share.
• The Series D Convertible Preferred Stock has anti-dilution provisions that could lead to further dilution of common stockholders if future securities are issued at a lower price, with no floor price on conversion.
• The company's current cash balance of $2,430 as of September 30, 2025, is extremely low, highlighting severe liquidity constraints.

Risks

• The company's ability to continue as a going concern is dependent on successful execution of its business development plan, including acquiring profitable companies, growing revenue, reducing operating costs, and accessing additional capital, which is not assured.
• If cash from operations is insufficient to meet operating needs and debt service, the business, financial condition, and results of operations may be materially adversely affected.
• Failure to raise additional capital will require curtailment or cessation of operations.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies or assets.
• The strategy to open new clinics in multiple markets makes it difficult to evaluate future business prospects and effectively manage growth, potentially increasing investment risk and harming financial results.
• Changes in tax laws and unanticipated tax liabilities could adversely affect the effective income tax rate and ability to achieve profitability.
• Quarterly financial results are expected to fluctuate significantly due to demand for services, client retention, economic conditions, marketing costs, and clinic expansion costs.
• Volatility in financial markets could have a material adverse effect on the business, making future financing difficult or more expensive.
• Potential profit margins may decline due to increasing pressure on margins in the industry.
• High indebtedness ($24.7 million as of Dec 31, 2024) could require a substantial portion of cash flow for debt service, reduce flexibility, and make additional financing difficult.
• Pandemics, epidemics, natural disasters, terrorist activities, political unrest, and other outbreaks could have a material adverse impact on business, results of operations, financial condition, and cash flows.
• Business interruptions from public health crises could disrupt clinic operations and adversely impact the business.
• The limited operating history of primary care clinics impedes the ability to evaluate future performance and strategy, and successful patient acquisition requires time and marketing investment.
• Acquisitions involve risks, including difficulties in integration and maintaining effective internal controls, which could adversely affect business and operating results.
• Failure to attract and retain qualified medical professionals (Nurse Practitioners) could negatively affect the ability to maintain operations, attract patients, or open new clinics.
• Difficulties in managing company growth could lead to higher operating losses or prevent growth altogether.
• Loss of key executives and failure to attract qualified managers could limit growth and negatively impact operations.
• The company may be subject to medical professional liability risks, which could be costly and negatively impact business and financial results.
• Billing Medicare, Medicaid, and TriCare programs presents significant compliance risks, fraud and abuse allegations, payment delays, audit risks, and regulatory changes.
• Operating primary care clinics in multiple states with varying commercial payer contracts creates additional administrative complexity, costs, and compliance risks.
• The evolving healthcare regulatory and political framework could adversely affect financial condition and results of operations.
• The highly regulated pharmacy practice, especially compounding, poses risks related to licensure, accreditation, compliance with FDA/USP standards, and potential liability issues.
• Dependence on consistent availability and quality of base pharmaceuticals for compounding creates supply chain disruption risks, potentially impacting personalized medication delivery and quality of life services.
• The quality of life services, based primarily on the self-pay model, carry risks of revenue volatility, bad debt, pricing challenges, and increased administrative costs.
• Changes in third-party reimbursement rates or methods for medical services could reduce demand or create downward pricing pressure, harming financial position.
• Federal and state restrictions on advertising may adversely affect the ability to advertise clinics and services.
• HIPAA compliance is critically important, and non-compliance could lead to fines, penalties, or criminal sanctions.
• Reliance on information technology means any failure, inadequacy, interruption, or security lapse could harm business operations.
• The highly competitive market for healthcare services could force price reductions, impacting revenues and results of operations.
• A decline in consumer disposable income could adversely affect clinical visits and financial results.
• Reduced disclosure requirements for smaller reporting companies may make common stock less attractive to investors.
• Requirements of being a public company may strain resources and distract management.
• Broad discretion in the use of net proceeds from the offering may not be effective, especially if acquisitions are unsuccessful.
• A limited trading market for common stock to date may impair liquidity and fair market value.
• The market for common stock may fluctuate significantly due to various factors, including changes in government regulation, reimbursement policies, and operating results.
• A significant percentage of common stock is held by a small number of shareholders, potentially influencing shareholder votes and corporate control.
• The issuance of common stock upon exercise of warrants held by selling stockholders could cause substantial dilution.
• Resales by selling stockholders under the Resale Prospectus may adversely affect the market price of common stock.
• The company has not paid dividends in the past and has no immediate plans to do so.
• Quarterly operating results are expected to fluctuate, potentially causing stock price decline.
• Penny stock rules may make buying or selling securities difficult, limiting liquidity.
• The former CEO's criminal conviction has tarnished the company's reputation and goodwill.
• Charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.
• Failure to achieve and maintain internal controls in accordance with Sarbanes-Oxley Act could have a material adverse effect on business and stock price.

Future Outlook

First Choice Healthcare Solutions plans to establish a national system of innovative, branded primary care and wellness clinics, leveraging two recent acquisitions (Pointe Med Pharmacy and The Good Clinic) and a centralized administrative infrastructure. The strategy focuses on personalized care, including anti-aging, weight management, and hormone replacement, delivered primarily by Nurse Practitioners to achieve higher margins. The company expects to commence new clinic operations by October 1, 2025, with a goal of opening 5 clinics by December 2025 and 30 new clinics within the next four years. A key part of the strategy involves expanding the acquired compounding pharmacy, LiveWell Drugstore, to supply personalized medications and potentially achieve FDA 503B status for broader market reach. The company anticipates achieving measurable cost and productivity efficiencies as its network of clinics grows.

Management Comments

• "Our go forward strategy will be executed using a corporate structure of centralized management services designated as Leading Primary Care, Inc. (which will be the Companys name after the proposed name change from First Choice Healthcare Solutions, Inc.) with three operating subsidiaries, Live Well Medical Group (comprised of the primary care clinic locations nationally), The Good Clinic Properties, Inc. (which holds leases on all physical clinic locations), and Live Well Drugstore, Inc. (comprised of our current and future compounding pharmacy operations)."
• "Although there are significant business, investment, and financial risks in launching this new healthcare concept, we believe our strategy of combining a full suite of primary care services and the specialized services of our competition in an operational environment focused on providing high quality care, excellent customer experience, personalized care plans and personalized medications has the potential to deliver our desired financial performance."
• "We believe that our centralized system of administrative infrastructure will allow us to achieve measurable cost and productivity efficiencies, as we expand the number of clinics we own and operate."
• "It is our plan that the cost of our back-office operations will not increase in direct relation to the growth of our network of primary care clinics, which will allow us to sustain profit margins across our business operations with a cost effective and scalable back office."
• "The Company believes that it will be successful in repairing its relationships with employees and referral sources, generating growth and improved profitability resulting in improved cash flows from operations."
• "Our opinion is that inflation has not had, and is not expected to have, a material effect on our operations."

Industry Context

The U.S. healthcare market is vast and growing, with expenditures reaching $4.5 trillion in 2022 (17.3% of GDP) and projected to hit $7.1 trillion by 2031 (19.6% of GDP). The primary care market alone was valued at $271.0 billion in 2023, with an expected CAGR of 3.36% through 2030. This growth is driven by an aging population and high prevalence of chronic conditions, alongside a recognized need to strengthen primary care. FCHS's pivot aligns with this trend, aiming to redefine primary care through personalization and a broad spectrum of services. The market is highly competitive, including virtual providers (Hims, Ro), brick-and-mortar clinics (Oak Street Medical, One Medical), and specialized clinics (Revibe, Herself Health). FCHS aims to differentiate through its comprehensive service suite, personalized care plans, and internal compounding pharmacy, while leveraging the cost advantage of Nurse Practitioners.

Comparison to Industry Standards

• The company's strategy to utilize Nurse Practitioners for primary care is noted to provide an approximate 25% margin improvement over traditional primary care offices staffed with medical doctors, based on Bureau of Labor Statistics data for May 2023 ($126,260 median annual pay for Nurse Practitioners vs. $240,790 for Family Medicine Physicians) and CMS reimbursement rates (85% of physician reimbursement).
• The U.S. healthcare market, with total spending at $4.5 trillion in 2022 (17.3% of GDP) and projected to reach $7.1 trillion by 2031 (19.6% of GDP), indicates a large and growing market opportunity for FCHS, aligning with broader industry trends.
• The U.S. primary care market, valued at $271.0 billion in 2023 and expected to grow at a CAGR of 3.36% from 2024 to 2030, provides a significant addressable market for FCHS's new strategy.
• The company acknowledges facing well-established, specialized competitors including virtual providers (e.g., Hims, Ro, REX MD, Renew Youth, Alloy, Midi), brick-and-mortar clinics (e.g., Revibe, Herself Health, Oak Street Medical, One Medical), and individual private practices, indicating a highly competitive landscape.
• Studies cited by the company (American Association of Nurse Practitioners, Barnett et al., Stanik-Hutt et al., Carranza et al.) support the claim that Nurse Practitioners deliver care equal to or better than physicians, providing a quality justification for their staffing model.

Management Changes

Corporate Governance

Legal Proceedings

• The company's former Chief Executive Officer, Christian C. Romandetti, Sr., pled guilty to conspiracy to commit securities fraud, which led to litigation and the company's bankruptcy filing in June 2020.
• The company exited bankruptcy on April 27, 2022, with all litigation settled or converted into unsecured creditors.
• An open accounts payable liability of approximately $1,200,000 remains from a lease settlement related to the Marina Towers property, with the company working to reach a settlement with the landlord.
• A complaint filed by Coastal Neurology, Inc. for breach of an escrow agreement and failure to pay $100,000 was withdrawn in 2024.
• A $19,473 judgment in favor of an equipment lease lessor was granted on January 25, 2024, which was subsequently settled for $9,000 in March 2024.
• The company is working to reach a settlement with CBL & Associates Properties, Inc. for $84,051 related to defaulted lease payments on a care facility.
• A motion for summary judgment was granted against the company for $102,884, including attorney fees and costs, in a breach of lease contract complaint filed by MBABJB Holdings Family Limited Partnership.
• The company has an unpaid legal fees balance of $203,115 to Ackerman, LLP, from bankruptcy proceedings, after defaulting on a payment plan.
• The company is a defendant in several employment-related matters, primarily due to unpaid wages following staff reductions and terminations, with most cases settled.

Related Party Transactions

• Pointe Med/Live Well group leases space under an operating lease agreement dated October 1, 2019, with Live Well Realty, LLC, which is a related party.
• As of September 30, 2025, the company has $2,142,105 in Other Non-Convertible Notes due to its Chief Executive Officer, Lance Friedman, related to deferred compensation, payments to third-party service providers, and other normal course of business items.
• As of September 30, 2025, the company has $151,858 in Other Non-Convertible Notes due to its prior Chief Financial Officer, related to deferred compensation, payments to third-party service providers, and other normal course of business items.
• The verbal agreement with the lessor regarding the exchange and settlement of FCHS's lease obligations for the Melbourne premises was with Omni Healthcare, Inc., whose principal was also an investor in FCHS, indicating a related party negotiation.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the public offering and potential future dilution due to anti-dilution provisions of Series D Preferred Stock. The 1-for-2,000 reverse stock split will drastically reduce the number of outstanding shares, potentially impacting per-share metrics. The cancellation of Series A Super Voting Preferred Stock will increase the relative voting power of common shareholders.
• Employees: Headcount reductions occurred in October 2021 and January 2023. The new strategy involves hiring key medical, sales, and management professionals, potentially creating new employment opportunities. However, the company faces risks in attracting and retaining qualified medical professionals.
• Customers/Patients: The strategic pivot aims to provide a 'more effective medical home' with personalized care plans, a broad spectrum of services, and an internal compounding pharmacy. The shift to primarily self-pay for 'quality of life' services could limit patient utilization or require discounts, impacting accessibility for some.
• Creditors: The offering proceeds will be used to settle some debt and liabilities, including SBA loans and other notes payable, which could improve the company's debt profile. However, significant outstanding liabilities and a 'going concern' warning indicate ongoing risk.
• Suppliers: The compounding pharmacy's dependence on consistent availability and quality of base pharmaceuticals creates supply chain risks, potentially affecting the company's ability to deliver personalized medications and quality of life services.

Next Steps

• Complete the public offering of Series D Convertible Preferred Stock and warrants, contingent on raising at least $10.0 million.
• Uplist common stock to the NYSE under the symbol FCHS.
• Complete the 1-for-2,000 reverse stock split immediately after the registration statement's effectiveness and prior to NYSE listing.
• Complete the stock purchase acquisition of Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC.
• Complete the asset purchase agreement to acquire assets of The Good Clinic, Inc.
• Commence operations for the new primary care and wellness clinics starting October 1, 2025.
• Open 5 new clinics by December 2025 and a total of 30 new clinics within the next four years.
• Attain FDA 503B pharmacy accreditation for LiveWell Drugstore to expand compounding services.
• Appoint new board members and re-establish Audit, Compensation, and Nominating & Governance Committees in the third quarter of 2025.
• Continue efforts to repair relationships with employees and referral sources, generate growth, improve profitability, and reduce operating costs.

Key Dates

Recommendation

First Choice Healthcare Solutions is undergoing a transformative strategic pivot into the high-growth primary care and wellness market, which presents significant long-term potential. The planned acquisitions of Pointe Med Pharmacy and The Good Clinic, along with the emphasis on Nurse Practitioners and an internal compounding pharmacy, offer a differentiated business model with potential for improved margins and patient experience. However, the company's historical financial performance is extremely weak, marked by substantial recurring net losses, negative operational cash flows, a large accumulated deficit, and a going concern warning from auditors. The success of the current $12 million capital raise is critical for the execution of this new strategy and for uplisting to the NYSE. While the strategic direction is promising, the execution risks are high, and the company's current financial health is precarious. Investors should 'hold' to observe the successful completion of the offering, the integration of acquisitions, and initial operational results of the new primary care model before considering further investment. The significant dilution for new investors and the anti-dilution provisions for preferred stock also warrant caution.

Keywords

Primary Care, Wellness Clinics, Healthcare Solutions, SEC Filing, S-1/A, IPO, Convertible Preferred Stock, Warrants, Compounding Pharmacy, Anti-aging, Weight Management, Hormone Replacement Therapy, Nurse Practitioners, Medical Acquisitions, NYSE Listing, Dilution, Going Concern, Healthcare Industry, Florida, Minnesota